Phase 2 × Multiple Myeloma × Alemtuzumab × Clear all
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts
NCT00698685 2017-03-31

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

University of Arizona

Phase 2 Terminated
14 enrolled 7 charts
NCT00109993 2010-06-11

Campath-1H + FK506 and Methylprednisolone for GVHD

Case Comprehensive Cancer Center

Phase 2 Completed
34 enrolled
NCT00410657 2010-05-14

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
53 enrolled